Researchers report azacitidine's first-day leukemia-cell killing acts mainly through RNA, not DNA
A Molecular Cell mechanistic study reports that azacitidine's early leukemia-cell killing is linked to rapid removal of m5C tags from chromatin-associated RNA, not DNA. The work identifies NSUN2 as a possible more precise target and challenges the drug's long-assumed DNA-centered mechanism. The finding is preliminary and does not by itself establish clinical benefit or patient response.
In the study, researchers examined how azacitidine, used for high-risk myelodysplastic syndromes and acute myeloid leukemia, behaves during the first 24 hours. They focused on early cell killing, when the drug is most active, rather than the slower DNA changes previously attributed to it. The team measured chemical tags on DNA and RNA and found a rapid drop in 5-methylcytosine on chromatin-associated RNA within eight hours, while DNA methylation did not change over the same period.
Using high-precision mass spectrometry, the researchers directly measured methyl-group levels over time. They also isolated proteins permanently bound to RNA and DNA after treatment, finding azacitidine engaged NSUN2, the enzyme that installs m5C tags on chromatin-associated RNA. That binding peaked at eight hours, the same time RNA methylation fell and genes needed for cell division and DNA repair began shutting down. The comparison with decitabine, which is designed for DNA uptake, helped separate RNA effects from DNA effects.
The result challenges the long-standing model that azacitidine works mainly as a DNA hypomethylating agent. Clinically, azacitidine helps only about a third to half of patients, and doctors lack reliable predictors of benefit. The researchers also note a paradox: decitabine is engineered to enter DNA more efficiently, yet azacitidine is used more widely, suggesting the active early mechanism may not be DNA-centered. If RNA effects drive early killing, NSUN2 becomes a candidate target for more selective therapy.
For patients with myelodysplastic syndromes and acute myeloid leukemia, the finding matters because it reframes why a decades-old drug works and identifies NSUN2 as a possible target. It also suggests RNA methylation may be a therapeutic route distinct from DNA methylation. The study is mechanistic, not a clinical trial, so it can show an early RNA effect in the tested systems, but it cannot establish that this mechanism explains all patient responses or that NSUN2-targeted drugs will be safe and effective.
People with myelodysplastic syndromes and acute myeloid leukemia are the affected group because azacitidine is a major treatment for them, and the study reframes the drug's early mechanism and identifies NSUN2 as a possible target.
Sources (1)
- [1]Original source(https://medicalxpress.com/news/2026-11-commonly-drug-leukemia-cells-early.html)